← Ranking

GILD · GILEAD SCIENCES, INC.

No alerts · No concrete new risks or important recent events

10-Q 2026-08-06 ↗ compared with the reference 10-K 10-K 2026-02-24 ↗

Closing price50-day average200-day average

Technical events and factor profile →

Summary

Gilead Sciences warns of potential EU regulations that could reduce data protection periods for its products and impose new obligations to supply across member states, and also faces evolving counterfeiting methods using AI.

Automatic summary generated from the filing; it may contain inaccuracies.
Concrete new risks
—
Generic new risks
—
Filing
10-Q · 2026-08-06

How the stock reacted

After the 10-Q1 session5 sessions20 sessions
GILD-0.7%+3.1%+13.5%
Nasdaq-100 (QQQ)-0.4%+0.9%-1.1%
Difference-0.3%+2.2%+14.7%

From the close before the filing. Historical data, not a prediction.

Key figures quarterly · USD

Revenue (TTM)
$30.5B
YoY growth
+10.2%
Operating margin
-133.2%
Cash / debt
$3.2B / $23.8B
Jun 26Mar 26Dec 25Sep 25Jun 25
Revenue$7.8B$7.0B$7.9B$7.8B$7.1B
YoY growth+10.2%+4.4%+4.7%+3.0%+1.8%
Gross margin—————
Operating margin-133.2%37.2%25.0%42.8%34.9%
Net income-$10.5B$2.0B$2.2B$3.1B$2.0B
Diluted EPS-8.451.611.752.431.56

XBRL data filed with the SEC. The fourth fiscal quarter is calculated as the full year minus the previous three quarters.

Factor profile percentile vs. the S&P 500 and the Nasdaq-100

Momentum
12 months excl. last: +30.7% · 6 months +14.9%
76
Trend quality
R² 0.67 · rising
88
Relative strength
+4.8% vs. the S&P 500 over 6 months
75
Volatility
25% annualised
32
Beta
beta 0.35
40
Distance from high
-0.7% from the 52-week high
94
Extension
+1.7 standard deviations from its 20-day average
64

0 = the lowest in the universe, 100 = the highest. It describes how the stock has behaved, not whether to buy or sell it. Screen stocks by factors

Management tone MD&A

+14

Similar than in the previous 10-Q (2026-05-07: +11, +3 points)

10-Q of 2026-08-06 · 29.8% positive sentences, 14.9% negative · 114 sentences analysed

Index from −100 to +100 calculated with FinBERT on the results discussion (MD&A). The change matters more than the level: some sectors always sound more cautious.

Top funds 13F

Bridgewater Associates · Ray Dalio
held since Q3 2023 or earlier
0.2% $36.7M +61%

Weight in each fund's portfolio and change vs. the previous quarter, from its latest 13F.

Recent material events (8-K)

2026-08-04 Results released 5 sessions: +1.1% vs Nasdaq-100 SEC ↗

All material events for GILD →

Insiders · last 90 days

Buys
—
Discretionary sells
—
10b5-1 plan sells
$4.0M
2026-10-15 Dickinson Andrew D · CFO Sell (10b5-1 plan) $469K SEC ↗
2026-10-15 Mercier Johanna · Officer Sell (10b5-1 plan) $469K SEC ↗
2026-10-01 O'Day Daniel Patrick · CEO Sell (10b5-1 plan) $1.8M SEC ↗
2026-10-01 O'Day Daniel Patrick · CEO Sell (10b5-1 plan) $446K SEC ↗
2026-09-15 Dickinson Andrew D · CFO Sell (10b5-1 plan) $436K SEC ↗
2026-09-15 Mercier Johanna · Officer Sell (10b5-1 plan) $230K SEC ↗
2026-09-15 Mercier Johanna · Officer Sell (10b5-1 plan) $116K SEC ↗
2026-09-15 Mercier Johanna · Officer Sell (10b5-1 plan) $87K SEC ↗

Source: SEC EDGAR. Automatic comparison of the risk factors section; it may contain extraction errors. Always check the original document. For information purposes only; not investment advice.